Edition:
United States

Madrigal Pharmaceuticals Inc (MDGL.OQ)

MDGL.OQ on NASDAQ Stock Exchange Capital Market

192.48USD
19 Oct 2018
Change (% chg)

$-6.49 (-3.26%)
Prev Close
$198.97
Open
$199.04
Day's High
$200.50
Day's Low
$191.01
Volume
55,351
Avg. Vol
82,032
52-wk High
$325.58
52-wk Low
$39.06

Select another date:

Tue, Sep 18 2018

Viking shares surge after fatty liver drug trial

Viking Therapeutics Inc's shares more than doubled in value on Tuesday after promising data from a mid-stage trial of its fatty liver drug were seen as topping that from larger rival Madrigal Pharmaceuticals .

Madrigal Pharma explores sale: Bloomberg

Madrigal Pharmaceuticals Inc is exploring a sale, Bloomberg reported on Wednesday, citing people familiar with the matter, nearly three weeks after the company reported mid-stage data from its drug to treat non-alcoholic steatohepatitis or NASH.

Madrigal Pharma explores sale - Bloomberg

June 13 Madrigal Pharmaceuticals Inc is exploring a sale, Bloomberg reported https://www.bloomberg.com/news/articles/2018-06-13/madrigal-pharma-is-said-to-explore-sale-amid-takeover-interest on Wednesday, citing people familiar with the matter, nearly three weeks after the company reported mid-stage data from its drug to treat non-alcoholic steatohepatitis or NASH.

Madrigal Pharma more than doubles after liver drug study success

Madrigal Pharmaceuticals Inc's shares more than doubled after mid-stage trial data showed its lead drug reduced liver fat in patients with fatty liver disease, placing it ahead of larger rivals to tap into a potential market worth $30 billion.

UPDATE 1-Madrigal Pharma's liver disease drug succeeds in study, shares soar

May 31 Madrigal Pharmaceuticals Inc said on Thursday its lead experimental drug achieved the main goal of reducing liver fat in patients with a type of liver disease in a mid-stage study, sending its shares surging 40 percent in premarket trading.

Madrigal Pharma's liver disease drug succeeds in mid-stage trial

May 31 Madrigal Pharmaceuticals Inc said on Thursday a mid-stage trial testing its lead experimental treatment for a liver disease achieved the main goal of reducing liver fat.

BRIEF-Madrigal Pharmaceuticals Reports Qtrly Loss Per Share Of $0.45

* MADRIGAL PHARMACEUTICALS REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS AND REVIEWS KEY CLINICAL ACHIEVEMENTS

Select another date: